Sagiv E - Search Results

1

CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis.

Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N. Sagiv E, et al. Gastroenterology. 2006 Aug;131(2):630-9. doi: 10.1053/j.gastro.2006.04.028. Gastroenterology. 2006. PMID: 16890615

2

Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA.

Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Sagiv E, et al. Cancer Res. 2008 Apr 15;68(8):2803-12. doi: 10.1158/0008-5472.CAN-07-6463. Cancer Res. 2008. PMID: 18413748

3

The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy.

Sagiv E, Arber N. Sagiv E, et al. Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):125-33. doi: 10.1586/17474124.2.1.125. Expert Rev Gastroenterol Hepatol. 2008. PMID: 19072375 Review.

4

CD24 plays an important role in the carcinogenesis process of the pancreas.

Sagiv E, Kazanov D, Arber N. Sagiv E, et al. Biomed Pharmacother. 2006 Jul;60(6):280-4. doi: 10.1016/j.biopha.2006.06.006. Epub 2006 Jun 23. Biomed Pharmacother. 2006. PMID: 16824727

5

Targeting the active beta-catenin pathway to treat cancer cells.

Dvory-Sobol H, Sagiv E, Kazanov D, Ben-Ze'ev A, Arber N. Dvory-Sobol H, et al. Among authors: sagiv e. Mol Cancer Ther. 2006 Nov;5(11):2861-71. doi: 10.1158/1535-7163.MCT-06-0122. Mol Cancer Ther. 2006. PMID: 17121933

6

Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.

Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. Dvory-Sobol H, et al. Among authors: sagiv e. Cancer. 2007 Jan 15;109(2):188-97. doi: 10.1002/cncr.22416. Cancer. 2007. PMID: 17149756 Free article.

7

Gene therapy approach in prostate cancer cells using an active Wnt signal.

Giladi N, Dvory-Sobol H, Sagiv E, Kazanov D, Liberman E, Arber N. Giladi N, et al. Among authors: sagiv e. Biomed Pharmacother. 2007 Oct;61(9):527-30. doi: 10.1016/j.biopha.2007.08.010. Epub 2007 Sep 14. Biomed Pharmacother. 2007. PMID: 17904788

8

Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes.

Sagiv E, Rozovski U, Kazanov D, Liberman E, Arber N. Sagiv E, et al. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6807-15. doi: 10.1158/1078-0432.CCR-07-1091. Clin Cancer Res. 2007. PMID: 18006783

9

Malignant transformation of normal enterocytes following downregulation of Bak expression.

Liberman E, Naumov I, Kazanov D, Dvory-Sobol H, Sagiv E, Birkenfeld S, Deutsch V, Trakhtenbrot L, Moshkowitz M, Arber N. Liberman E, et al. Among authors: sagiv e. Digestion. 2008;77(1):48-56. doi: 10.1159/000121411. Epub 2008 Mar 18. Digestion. 2008. PMID: 18349538

10

Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.

Sagiv E, Sheffer M, Kazanov D, Shapira S, Naumov I, Kraus S, Domany E, Arber N. Sagiv E, et al. Digestion. 2011;84(3):169-84. doi: 10.1159/000322688. Epub 2011 May 5. Digestion. 2011. PMID: 21546775

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters